200 related articles for article (PubMed ID: 19192165)
1. Hepatosplenic T-cell lymphomas and therapy with TNF-alpha-blocking biologics: a risk for psoriasis patients?
Beyer M; Steinhoff M; Anagnostopoulos I; Assaf C; Sterry W
J Dtsch Dermatol Ges; 2009 Mar; 7(3):191-4. PubMed ID: 19192165
[TBL] [Abstract][Full Text] [Related]
2. T-cell non-Hodgkin's lymphomas reported to the FDA AERS with tumor necrosis factor-alpha (TNF-α) inhibitors: results of the REFURBISH study.
Deepak P; Sifuentes H; Sherid M; Stobaugh D; Sadozai Y; Ehrenpreis ED
Am J Gastroenterol; 2013 Jan; 108(1):99-105. PubMed ID: 23032984
[TBL] [Abstract][Full Text] [Related]
3. Hepatosplenic T-cell lymphoma in patients receiving TNF-α inhibitor therapy: expanding the groups at risk.
Parakkal D; Sifuentes H; Semer R; Ehrenpreis ED
Eur J Gastroenterol Hepatol; 2011 Nov; 23(12):1150-6. PubMed ID: 21941193
[TBL] [Abstract][Full Text] [Related]
4. Hepatosplenic T cell lymphoma associated with infliximab use in young patients treated for inflammatory bowel disease.
Mackey AC; Green L; Liang LC; Dinndorf P; Avigan M
J Pediatr Gastroenterol Nutr; 2007 Feb; 44(2):265-7. PubMed ID: 17255842
[TBL] [Abstract][Full Text] [Related]
5. Review article: anti TNF-alpha induced psoriasis in patients with inflammatory bowel disease.
Fiorino G; Allez M; Malesci A; Danese S
Aliment Pharmacol Ther; 2009 May; 29(9):921-7. PubMed ID: 19210297
[TBL] [Abstract][Full Text] [Related]
6. Hepatosplenic T-cell lymphoma and inflammatory bowel disease.
Thai A; Prindiville T
J Crohns Colitis; 2010 Nov; 4(5):511-22. PubMed ID: 21122554
[TBL] [Abstract][Full Text] [Related]
7. A systematic review of factors that contribute to hepatosplenic T-cell lymphoma in patients with inflammatory bowel disease.
Kotlyar DS; Osterman MT; Diamond RH; Porter D; Blonski WC; Wasik M; Sampat S; Mendizabal M; Lin MV; Lichtenstein GR
Clin Gastroenterol Hepatol; 2011 Jan; 9(1):36-41.e1. PubMed ID: 20888436
[TBL] [Abstract][Full Text] [Related]
8. Management of moderate to severe plaque psoriasis (part I): clinical update on antitumor necrosis factor agents.
Sobell JM; Kalb RE; Weinberg JM
J Drugs Dermatol; 2009 Feb; 8(2):147-54. PubMed ID: 19213230
[TBL] [Abstract][Full Text] [Related]
9. [Infectious risk].
Calabuig E; Salavert M
Actas Dermosifiliogr; 2008 Jul; 99 Suppl 4():14-22. PubMed ID: 19080987
[TBL] [Abstract][Full Text] [Related]
10. Sustained effects of low dose infliximab in combination with methotrexate in the management of chronic recalcitrant psoriasis.
Zargari O
Dermatol Online J; 2005 Dec; 11(3):21. PubMed ID: 16409917
[TBL] [Abstract][Full Text] [Related]
11. Cutaneous manifestations in inflammatory bowel diseases: eight cases of psoriasis induced by anti-tumor-necrosis-factor antibody therapy.
Passarini B; Infusino SD; Barbieri E; Varotti E; Gionchetti P; Rizzello F; Morselli C; Tambasco R; Campieri M
Dermatology; 2007; 215(4):295-300. PubMed ID: 17911986
[TBL] [Abstract][Full Text] [Related]
12. Effects of tumor necrosis factor-alpha blockade on metabolic syndrome components in psoriasis and psoriatic arthritis and additional lessons learned from rheumatoid arthritis.
Channual J; Wu JJ; Dann FJ
Dermatol Ther; 2009; 22(1):61-73. PubMed ID: 19222518
[TBL] [Abstract][Full Text] [Related]
13. Safety of infliximab and other biologic agents in the inflammatory bowel diseases.
Reddy JG; Loftus EV
Gastroenterol Clin North Am; 2006 Dec; 35(4):837-55. PubMed ID: 17129816
[TBL] [Abstract][Full Text] [Related]
14. Etanercept provides a more physiological approach in the treatment of psoriasis.
Altomare G; Ayala F; Berardesca E; Chimenti S; Giannetti A; Girolomoni G; Lotti T; Martini P; Peserico A; Guerra AP; Vena GA
Dermatol Ther; 2008 Oct; 21 Suppl 2():S1-14. PubMed ID: 18837727
[TBL] [Abstract][Full Text] [Related]
15. The role of lesional T cells in recalcitrant psoriasis during infliximab therapy.
Bovenschen HJ; Van De Kerkhof PC; Gerritsen WJ; Seyger MM
Eur J Dermatol; 2005; 15(6):454-8. PubMed ID: 16280298
[TBL] [Abstract][Full Text] [Related]
16. Long-term prognosis in patients with psoriasis.
Gulliver W
Br J Dermatol; 2008 Aug; 159 Suppl 2():2-9. PubMed ID: 18700909
[TBL] [Abstract][Full Text] [Related]
17. [Psoriasis in the era of biologics].
Torres T; Velho GC; Sanches M; Selores M
Acta Med Port; 2010; 23(3):493-8. PubMed ID: 20654269
[TBL] [Abstract][Full Text] [Related]
18. The impact of treatment with tumour necrosis factor-alpha antagonists on the course of chronic viral infections: a review of the literature.
Domm S; Cinatl J; Mrowietz U
Br J Dermatol; 2008 Dec; 159(6):1217-28. PubMed ID: 18945310
[TBL] [Abstract][Full Text] [Related]
19. How to manage infections in the era of biologics?
Saraceno R; Chimenti S
Dermatol Ther; 2008; 21(3):180-6. PubMed ID: 18564248
[TBL] [Abstract][Full Text] [Related]
20. Biologic therapies for psoriasis.
de Felice C; Ardigo M; Berardesca E
J Rheumatol Suppl; 2009 Aug; 83():62-4. PubMed ID: 19661545
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
